Department of Psychology and Neuroscience, Dalhousie University, Life Sciences Centre, 1355 Oxford Street, PO Box 15000, Halifax, Nova Scotia, B3H 4R2, Canada.
Department of Psychiatry, Dalhousie University, Life Sciences Centre, 1355 Oxford Street, PO Box 15000, Halifax, Nova Scotia, B3H 4R2, Canada.
Psychopharmacology (Berl). 2021 Jul;238(7):1965-1977. doi: 10.1007/s00213-021-05823-w. Epub 2021 Apr 4.
Cannabidiol (CBD) has been reported to attenuate stress and anxiety, but little is known about the extent to which such effects result from pharmacological versus expectancy factors.
We evaluated whether CBD expectancy alone could influence stress, anxiety, and mood, and the extent to which beliefs regarding CBD effects predicted these responses.
In this randomized crossover study, 43 health adults (23 women) attended two experimental laboratory sessions, where they self-administered CBD-free hempseed oil sublingually. During one session, they were (incorrectly) informed that the oil contained CBD and in the other session, that the oil was CBD-free. Following administration, participants engaged in the Maastricht Acute Stress Test (MAST). Heart rate variability (HRV) was assessed continuously, and subjective state was assessed at baseline, 90-min following oil administration, immediately following the MAST, and after a 10-min recovery period.
The CBD expectancy condition was associated with increased sedation as well as with changes in HRV that were consistent with heightened anticipatory stress regulation. Overall, there were no systematic changes in subjective stress, or anxiety, according to expectancy condition. However, participants who endorsed strong a priori beliefs that CBD has anxiolytic properties reported significantly diminished anxiety in the CBD expectancy condition.
CBD expectancy alone impacted several subjective and physiological responses. Additionally, expectancy-related factors were implicated in anxiolytic effects of CBD for those who believed it was helpful for such purposes, emphasizing the need to measure and control for CBD-related expectancies in clinical research that involves the administration of CBD.
据报道，大麻二酚（CBD）可减轻压力和焦虑，但人们对这些作用是源于药理学还是预期因素知之甚少。
我们评估了 CBD 的预期作用是否会单独影响压力、焦虑和情绪，以及对 CBD 作用的信念在多大程度上预测了这些反应。
在这项随机交叉研究中，43 名健康成年人（23 名女性）参加了两次实验性实验室会议，他们在舌下自我给予 CBD 无的大麻籽油。在一次会议中，他们被（错误地）告知油中含有 CBD，而在另一次会议中，他们被告知油中不含 CBD。给药后，参与者进行了马斯特里赫特急性应激测试（MAST）。连续评估心率变异性（HRV），并在基线、油给药后 90 分钟、MAST 后立即以及 10 分钟恢复期后评估主观状态。
CBD 预期条件与镇静作用增加以及 HRV 的变化有关，这些变化与预期应激调节增强一致。总体而言，根据预期条件，主观压力或焦虑没有系统变化。然而，那些事先强烈认为 CBD 具有抗焦虑特性的参与者在 CBD 预期条件下报告的焦虑明显减轻。
单独的 CBD 预期作用会影响几个主观和生理反应。此外，对于那些认为 CBD 有助于缓解焦虑的人，预期相关因素与 CBD 的抗焦虑作用有关，这强调了在涉及 CBD 给药的临床研究中需要测量和控制与 CBD 相关的预期的必要性。
